The government of India has placed an order of 300 million vaccine doses of a new vaccine called ‘Corbevax’. This vaccine is being developed by the company called ‘Biological E.’ which is based in Hyderabad city.
The Corbevax vaccine is currently in the third phase of trials and they are expected to be finished by the end of July. It is quite odd to see that the government has placed an order without the successful completion of the trials.
The Corbevax vaccine is considered different because it is a “recombinant protein sub-unit”. The protein that is being used in the production of Corbevax is the ‘SARS-CoV-2’. This vaccine contains only the spike protein unit without the virus. It is believed that because of this difference, the vaccine cannot cause any harm.
After reacting to this spike protein, the body creates an immune response and makes the person more resistant to the infection.
The raw materials used in the production of the Corbevax vaccine are very cheap and easy to procure compared to other vaccines. It has been announced that once the phase 3 trials are completed, the approval process will start and finally the production will begin.
Corbevax vaccine will have two doses to ensure maximum efficacy. Corbevax is expected to be the cheapest vaccine in India. The Corbevax vaccine has received funding from the government to ensure the smooth conclusion of its production.